Please assess the completion status of the following clinical trial:

Trial Title: A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients 18 to 80 years of age, self-identified as Hispanic or Latino ethnicity~* Females must be post-menopausal, or not pregnant and using an approved contraceptive regimen~* Meet criteria for stage I or II hypertension~* Currently not treated, or being treated with no more than two anti-hypertensive medications~Exclusion Criteria:~* Secondary hypertension~* Are taking three or more antihypertensive agents~* Have uncontrolled or poorly controlled diabetes mellitus type I or type II~* Evidence of other concurrent disease or conditions that might interfere with the conduct of the study~* Participation in any investigational study within 30 days of Screening (Visit 1).~* Have a history of hypersensitivity to nebivolol or other β-blockers, or any contraindication to β-blocker use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Nebivolol (Type: ACTIVE_COMPARATOR): Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets, oral administration
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets, oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).